Entera Bio Ltd.
Oral tablet formulations of peptide and protein therapeutics for systemic delivery
- Sector
- Biotech
- Headquarters
- JERUSALEM, L3
- Latest Form D
- $6.6M, Jan 2024
- Total capital
- $22.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $22.2M
- 3 Form D · last Jan 2024
- 34 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 14 pending · first 2018
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$6.6M
- Private capital raisedForm D · SEC · 2nd filing$13.5M
- Private capital raisedForm D · SEC · 1st filing$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Adam GridleyExecutive Officer, DirectorNamed in SEC Form D filings
- Arthur SantoraExecutive OfficerNamed in SEC Form D filings
- Chaim M. DavisDirectorNamed in SEC Form D filings
- Dana YaacovExecutive OfficerNamed in SEC Form D filings
- Dana Yaacov-GarbeliExecutive OfficerNamed in SEC Form D filings
- David M. Ben AmiDirectorNamed in SEC Form D filings
Show all 20 people
- Faith CharlesDirectorNamed in SEC Form D filings
- Gerald LiebermanDirectorNamed in SEC Form D filings
- Gerald M. OstrovDirectorNamed in SEC Form D filings
- Gerald OstrovDirectorNamed in SEC Form D filings
- Haya TaitelDirectorNamed in SEC Form D filings
- Hillel GalitzerExecutive OfficerNamed in SEC Form D filings
- Luke M. BesharDirectorNamed in SEC Form D filings
- Miranda ToledanoExecutive OfficerNamed in SEC Form D filings
- Phillip SchwartzExecutive Officer, DirectorNamed in SEC Form D filings
- Roger M. GarceauDirectorNamed in SEC Form D filings
- Ron MayronDirectorNamed in SEC Form D filings
- Sean EllisDirectorNamed in SEC Form D filings
- Yonatan M. MalcaDirectorNamed in SEC Form D filings
- Zeev M. BronfeldDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 21- PendingFormulations Comprising A Combination Of Acid-neutralizing Polymeric And Non-polymeric Substances For Oral Administration Of Active AgentsUSPTOApplication 19544782
- PendingFormulations Comprising Acid-neutralizing Polymer For Oral Administration Of Parathyroid HormoneUSPTOApplication 19440230
- PendingMethods And Compositions For Oral AdministrationUSPTOApplication 19218293
Show all 21 patent records
- Formulations Comprising A Combination Of Acid-neutralizing Polymeric And Non-polymeric Substances For Oral Administration Of Active AgentsJul 2, 2026 · Application 19544782Pending
- Formulations Comprising Acid-neutralizing Polymer For Oral Administration Of Parathyroid HormoneMay 7, 2026 · Application 19440230Pending
- Methods And Compositions For Oral AdministrationSep 11, 2025 · Application 19218293Pending
- Formulations Comprising Acid-neutralizing Polymer For Oral Administration Of Glucagon-like PEPTIDE-2Jun 12, 2025 · Application 18841378Pending
- Formulations Comprising Acid-neutralizing Polymer For Oral Administration Of Parathyroid HormoneJun 12, 2025 · Application 18841379Pending
- Formulations Comprising Acid-neutralizing Polymer For Oral Administration Of Glucagon-like PEPTIDE-1 And Analogs ThereofJun 12, 2025 · Application 18841375Pending
- Formulations Comprising Acid-neutralizing Polymer For Oral Administration Of Active AgentsJun 12, 2025 · Application 18841377Pending
- Methods And Compositions For Oral AdministrationMay 27, 2025 · US 12,311,051Granted
- Formulations For Oral Administration Of Active AgentsMar 4, 2025 · US 12,239,691Granted
- Formulations For Oral Administration Of Active AgentsDec 19, 2024 · Application 18818691Pending
- Formulations For Oral Administration Of Active AgentsDec 5, 2024 · Application 18798864Pending
- Formulations For Oral Administration Of Active AgentsSep 3, 2024 · US 12,076,373Granted
- Treatment Of HypoparathyroidismJun 6, 2024 · Application 18432185Pending
- Methods And Compositions For Oral AdministrationFeb 15, 2022 · US 11,246,827Granted
- Formulations For Oral Administration Of Active AgentsMar 10, 2020 · US 10,583,177Granted
- Methods And Compositions For Oral AdministrationSep 24, 2019 · US 10,420,721Granted
- Methods And Compositions For Oral AdministrationJul 3, 2018 · US 10,010,503Granted
- Treatment Of HypoparathyroidismFeb 22, 2018 · Application 15549442Pending
- Formulations For Oral Administration Of Active Agents With Controlled Absorption ProfileFeb 8, 2018 · Application 15549394Pending
- Treatment Of Bone Fractures And DefectsFeb 8, 2018 · Application 15549418Pending
- Treatment Of OsteoporosisFeb 1, 2018 · Application 15549425Pending
Related companies, and why
- TheraCea Pharma LCSimilar federal contract value in Biotech · null in contracts
- SightStream Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- KAIO Therapy, LLCSimilar federal contract value in Biotech · null in contracts
- BIOCARDIA LIFESCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Cerberus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Mi-Helper, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .